List of Excipients in Branded Drug ALBUMINAR-25

ALBUMINAR-25 Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

ALBUMINAR-25 is a 25% human albumin biologic supplied as an intravenous solution. Its formulation uses sodium caprylate and sodium acetyltryptophanate as stabilizing excipients, with sodium chloride contributing to ionic balance. The product’s commercial protection is driven primarily by FDA biologics regulation, manufacturing controls, plasma sourcing, viral safety, and hospital contracting rather than by a modern composition-of-matter patent estate.[1]

The strongest opportunities are in excipient supply assurance, container-closure systems, albumin manufacturing technology, regional product registrations, and differentiated albumin presentations. A conventional generic pathway is not available because ALBUMINAR-25 is a biologic product rather than a small-molecule drug eligible for an ANDA.

What is ALBUMINAR-25 and how is it formulated?

ALBUMINAR-25 contains human albumin at a concentration of 25 g per 100 mL. It is administered intravenously and is used in clinical settings that require plasma volume expansion or albumin replacement, subject to the approved prescribing information.[1]

ALBUMINAR-25 formulation profile

Component	Function	Commercial relevance
Human albumin	Active biologic ingredient	Requires qualified human plasma, fractionation, purification, viral clearance and extensive release testing
Sodium caprylate	Albumin stabilizer	Supports protein stability during processing and storage
Sodium acetyltryptophanate	Albumin stabilizer	Reduces protein denaturation and aggregation risk
Sodium chloride and associated ions	Tonicity and formulation control	Requires control of sodium concentration and osmolality
Water for injection	Vehicle	Must meet compendial and injectable-product standards

The FDA label identifies sodium caprylate and sodium acetyltryptophanate as stabilizing formulation components. The labeled product has a controlled pH range and defined sodium and potassium limits, which constrain substitution with alternative excipients.[1]

What excipients protect the stability of ALBUMINAR-25?

The core excipient strategy is based on two stabilizers rather than on a novel proprietary additive system.

Sodium caprylate

Sodium caprylate, also known as sodium octanoate, is a fatty-acid salt used in albumin formulations to stabilize the protein structure. It can reduce susceptibility to heat-related denaturation and interfacial stress during manufacturing, filling and storage.

For suppliers, the relevant specifications include:

• Assay and impurity profile
• Residual solvents
• Elemental impurities
• Microbial and endotoxin limits
• Bioburden control
• Lot-to-lot consistency
• Compatibility with albumin purification and filtration steps

An excipient supplier seeking to displace an incumbent would need to demonstrate equivalent performance in aggregation, turbidity, subvisible particles, potency and accelerated stability studies. A lower-cost material without equivalent impurity control is unlikely to create a viable commercial position.

Sodium acetyltryptophanate

Sodium acetyltryptophanate is another established albumin stabilizer. Its commercial value is higher than its unit price would suggest because albumin manufacturers must control its identity, concentration, degradation products and compatibility with the protein purification process.

Potential supplier advantages include:

• Dedicated GMP manufacturing
• Validated analytical methods
• Reliable global supply
• Low residual impurity burden
• Regulatory documentation suitable for biologics manufacturing
• Dual sourcing from qualified production sites

The key opportunity is supply-chain qualification, not exclusivity over the excipient itself. Both stabilizers are established formulation materials and are unlikely to provide a defensible standalone patent position around ALBUMINAR-25.

What formulation patents protect ALBUMINAR-25?

The public FDA prescribing information does not identify an active composition patent, formulation patent or Orange Book-listed patent for ALBUMINAR-25.[1] Albumin formulations using caprylate and acetyltryptophanate have been used for decades, making a broad, enforceable patent claim over the basic formulation unlikely.

Patent strength assessment

Asset category	Assessment	Commercial impact
Human albumin composition	Weak or expired as a patent strategy	Albumin is an established biologic substance
25% concentration	Weak	Concentration alone is unlikely to create durable exclusivity
Sodium caprylate stabilizer	Weak for broad claims	Established excipient and known albumin stabilizer
Sodium acetyltryptophanate	Weak for broad claims	Established formulation component
Specific manufacturing process	Potentially stronger	Could protect yield, purity, viral clearance or aggregation control
Container-closure system	Potentially protectable	May support a differentiated presentation or shelf-life profile
Device or administration system	Potentially protectable	Relevant if paired with a proprietary delivery or infusion system
Analytical or process-control method	Narrow but commercially useful	Can protect quality-control workflows or process implementation

The more credible patent opportunities are process-specific. Examples include improved plasma fractionation, chromatography sequences, nanofiltration, viral inactivation, low-aggregation processing, high-concentration filling, and methods that improve yield or reduce manufacturing loss.

When does ALBUMINAR-25 lose exclusivity?

ALBUMINAR-25 does not have a conventional small-molecule exclusivity timeline. It is regulated as a licensed biologic under the Public Health Service Act, and market entry is governed by biologics licensing and comparability requirements rather than by an ANDA-based generic system.[2]

The FDA label identifies ALBUMINAR-25 as a human albumin product marketed by CSL Behring LLC. The relevant regulatory barrier is continued compliance with the biologics license, current good manufacturing practice requirements, plasma-sourcing controls and postmarket obligations.[1]

Exclusivity timeline

Protection type	Relevance to ALBUMINAR-25
Small-molecule NCE exclusivity	Not applicable
Hatch-Waxman five-year exclusivity	Not applicable
Orange Book patent term	Not the primary framework
Biologic reference-product exclusivity	Relevant to follow-on biologic timing, depending on the reference product and approval history
Manufacturing know-how	Potentially material and may remain confidential indefinitely
Plasma and supplier qualification	Commercial barrier with no fixed statutory expiration
BLA approval	Continues while the product remains compliant and marketed

A competing manufacturer would generally pursue a separate biologics license or a biosimilar application, not an ANDA. The existence of a biosimilar pathway does not eliminate the technical burden of demonstrating similarity for a complex plasma-derived protein.

What is the Orange Book status of ALBUMINAR-25?

ALBUMINAR-25 is not expected to have the same Orange Book patent-listing profile as an FDA-approved small-molecule drug. The Orange Book is primarily used for approved drug products and associated patents relevant to ANDA certifications. Biologic products are generally assessed through the Purple Book and the Public Health Service Act framework.[2,3]

Paragraph IV challenge risk

A conventional Paragraph IV challenge is not the principal risk for ALBUMINAR-25. Because a competitor would not normally rely on an ANDA pathway for a plasma-derived albumin product, there is no conventional Paragraph IV launch sequence comparable to that for branded tablets or capsules.

The relevant competitive challenges are:

• A standalone biologics license application
• A biosimilar application under section 351(k)
• A product with a different formulation and separate clinical or comparability package
• Regional approval of another licensed human albumin product
• Hospital substitution based on formulary and supply considerations

No broadly recognized Paragraph IV litigation strategy is associated with ALBUMINAR-25.

What biosimilar risks affect ALBUMINAR-25?

The biosimilar risk is technically possible but commercially more complex than the risk for a well-characterized monoclonal antibody.

Albumin is a defined protein, but a follow-on applicant must address:

• Primary amino-acid sequence
• Higher-order structure
• Impurity profile
• Aggregation and particle formation
• Post-translational modifications
• Binding and functional activity
• Plasma source and fractionation controls
• Viral clearance
• Stability across the proposed shelf life
• Container-closure compatibility

A biosimilar applicant may seek approval through the 351(k) pathway, but the absence of an established albumin biosimilar market limits precedent for interchangeability, substitution and payer treatment. The Purple Book is the relevant FDA reference for licensed biological products and biosimilar approvals.[3]

A follow-on albumin product could still compete without being designated interchangeable. Hospitals may purchase based on price, reliability, shortage history, formulary status and contract terms rather than automatic pharmacy substitution.

What manufacturing and intellectual-property barriers protect the product?

The principal barrier is the integrated manufacturing system.

Plasma supply

Human albumin depends on a reliable supply of qualified human plasma. Commercial barriers include donor recruitment, plasma collection infrastructure, infectious-disease testing, traceability and regulatory controls. New entrants cannot quickly replicate an established plasma network.

Fractionation and purification

Albumin production requires large-scale fractionation and purification. Process performance must control:

• Albumin recovery
• Immunoglobulin and protein impurities
• Host-derived contaminants
• Viral reduction
• Endotoxin and bioburden
• Aggregates and particles
• Fill-finish losses

Process patents may provide value where they materially improve yield, purity or stability. Confidential know-how may be more important than published patents because manufacturing performance depends on process parameters, equipment configuration and operator controls.

Viral safety

Viral inactivation and removal are central to regulatory approval. Any change to solvent-detergent treatment, heat treatment, nanofiltration or other viral-clearance steps can trigger extensive comparability work.

Container closure

A 25% albumin product is sensitive to adsorption, agitation, extractables and storage conditions. Opportunities include:

• Low-binding glass or polymer containers
• Improved stopper and seal systems
• Reduced headspace oxygen
• Lower particulate generation
• More robust shipping configurations
• Longer shelf life
• Alternative vial sizes or ready-to-use presentations

These improvements could support new product claims if validated in stability studies and accepted by FDA.

Which companies compete with ALBUMINAR-25?

Competition comes from other human albumin manufacturers rather than from conventional generic-drug companies.

Competitive category	Examples of commercial positioning
Human albumin 25%	Competes directly on concentration, supply reliability and hospital price
Human albumin 20%	May compete where clinicians accept a different concentration
Human albumin 5%	Targets volume expansion with lower albumin concentration
Other plasma-derived biologics	Compete for fractionation capacity and hospital budgets
Potential follow-on albumin products	Could compete through biosimilar or standalone biologics pathways
Recombinant albumin	Could reduce dependence on human plasma if regulatory and economic barriers are overcome

Major albumin suppliers have included CSL Behring, Grifols, Takeda and Kedrion, depending on jurisdiction and product registration. Product availability differs by country, and hospital purchasing often depends on national tenders and supply contracts.

What commercial opportunities exist in the ALBUMINAR-25 value chain?

1. Excipient dual sourcing

A qualified supplier of pharmaceutical-grade sodium caprylate or sodium acetyltryptophanate can target albumin manufacturers with a supply-continuity proposition. The strongest selling points are regulatory support, redundant manufacturing capacity and validated quality rather than material price alone.

2. Alternative container systems

A container supplier could develop a low-binding, low-particulate presentation for concentrated albumin. Commercial value would depend on demonstrated stability, compatibility and reduced shipping or administration losses.

3. Manufacturing-process licensing

Technology that increases albumin recovery, shortens purification cycles or improves viral-clearance robustness may support licensing to plasma fractionators. Process rights are more defensible when they produce measurable cost savings or improve batch release consistency.

4. Regional manufacturing partnerships

Countries that rely on imported plasma-derived products may create opportunities for local fill-finish, regional distribution or technology transfer. Full local fractionation is more difficult because it requires plasma infrastructure and extensive regulatory oversight.

5. Hospital and tender optimization

Albumin is purchased through hospitals, group purchasing organizations and national tender systems. A supplier with secure inventory, multiple vial sizes and predictable delivery may win business even without a patent advantage.

6. Reduced-waste presentations

Smaller or flexible package sizes may reduce unused product after opening. A differentiated presentation could improve procurement economics, especially in lower-volume hospitals and markets with strict wastage controls.

How does ALBUMINAR-25 compare with other albumin products?

Attribute	ALBUMINAR-25	20% human albumin	5% human albumin
Albumin concentration	25 g/100 mL	20 g/100 mL	5 g/100 mL
Primary commercial distinction	High concentration	Intermediate concentration	Volume expansion
Excipient strategy	Stabilized albumin solution	Similar established stabilizer approach may apply	Similar established stabilizer approach may apply
Patent differentiation	Limited	Limited	Limited
Regulatory barrier	Biologic manufacturing and BLA compliance	Same	Same
Main competitive factors	Supply, price, purity, formulation and contracting	Same	Same
Generic substitution	Not applicable through ANDA	Not applicable through ANDA	Not applicable through ANDA

The concentration difference can create clinical and purchasing preferences, but it does not by itself create a strong patent moat.

What is the revenue exposure and launch risk?

CSL Behring does not generally disclose ALBUMINAR-25 revenue as a standalone product line in public financial reporting. Product-level revenue exposure therefore cannot be reliably quantified from issuer disclosures.

A new entrant would face three launch scenarios:

1. A premium differentiated product with improved stability, packaging or supply reliability.
2. A price-led competing albumin product approved under a separate biologics pathway.
3. A biosimilar or highly similar albumin product competing for hospital contracts.

The highest-probability commercial threat is a lower-priced, supply-reliable competing albumin product. The lowest-probability near-term threat is a broad substitution event based solely on a novel excipient system.

Key Takeaways

• ALBUMINAR-25 is a 25% human albumin biologic manufactured under a BLA framework.
• Sodium caprylate and sodium acetyltryptophanate are the central stabilizing excipients.
• The basic formulation has limited apparent patent strength because the excipient system is longstanding.
• Orange Book and Paragraph IV strategies are not the primary competitive framework.
• Biosimilar or separate biologics entry is possible but requires substantial analytical, manufacturing and regulatory work.
• The strongest barriers are plasma sourcing, fractionation, viral safety, process know-how and hospital contracting.
• The most practical commercial opportunities are excipient dual sourcing, container systems, process licensing, regional supply and reduced-waste packaging.
• No standalone ALBUMINAR-25 revenue figure is publicly disclosed.

FAQs About ALBUMINAR-25 Excipient and Patent Opportunities

Is sodium caprylate a patented excipient for ALBUMINAR-25?

No broad product-specific patent protection should be assumed. Sodium caprylate is an established albumin stabilizer. Commercial value is more likely to arise from GMP supply, quality consistency and regulatory qualification.

Can a generic drug company file an ANDA for ALBUMINAR-25?

No. A competing manufacturer would generally need a biologics license application or a biosimilar application rather than an ANDA.

Could recombinant albumin replace ALBUMINAR-25?

Potentially, but recombinant albumin would need to match the required quality, safety, functionality, manufacturing scale and cost profile. Its main strategic advantage would be reduced dependence on human plasma.

Are formulation changes to ALBUMINAR-25 commercially protectable?

Yes, if a new formulation produces validated improvements in stability, shelf life, aggregation, container compatibility or administration. Patent protection would likely be narrow and dependent on specific composition and performance data.

What is the most defensible commercial opportunity around ALBUMINAR-25?

The strongest opportunity is usually a manufacturing or supply-chain improvement that reduces batch failure, increases albumin recovery, improves stability or guarantees excipient and container supply. These advantages can be commercially meaningful even without composition patents.

References

1. U.S. Food and Drug Administration. (n.d.). Albuminar-25: Albumin (Human) injection, solution prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Biologics license applications and the biologics approval process. https://www.fda.gov/

3. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/